Skip to main content
. Author manuscript; available in PMC: 2023 Jan 17.
Published in final edited form as: Nat Biotechnol. 2021 Feb 23;39(6):747–753. doi: 10.1038/s41587-021-00839-1

Figure 3.

Figure 3.

Experimental validation results from the sencondary confirmation of model predicted actives. A. Potencies and examples of compounds confirmed in the EBOV inhibition assay with minimal cytotoxicity. Replicate data are presented as mean±SD. B. Potencies and examples of compounds confirmed in the ZIKV NS1 inhibition assay with minimal cytotoxicity. Replicate data (n = 3) are presented as mean±SD. C. Potencies and examples of compounds confirmed in the anti-SARS-CoV-2 CPE assay.